Kenneth P. Olive

PHGDH is a targetable driver of PDAC progression

This study identifies PHGDH as a driver of PDAC progression by maintaining glutamine metabolism and mTOR signaling, revealing a therapeutic vulnerability to glutamine antagonism in PHGDH-deficient tumors.

Combined HDAC and eIF4A inhibition: A novel epigenetic therapy for pancreatic adenocarcinoma

This paper shows that combining HDAC and eIF4A inhibitors effectively treats pancreatic cancer by inducing epigenetic reprogramming and metabolic stress in preclinical models.

Netrin-1 promotes pancreatic tumorigenesis and innervation through NEO1.

This study identifies NTN1/NEO1 as a key driver of pancreatic tumorigenesis and metastasis by promoting cancer stemness, EMT, and nerve innervation.

Tumor-selective treatment of metastatic pancreatic cancer with an engineered, probiotic living drug

This study engineers a probiotic bacteria to selectively target pancreatic cancer, improving survival and modulating the tumor microenvironment.

Pre-clinical validation of an RNA-based precision oncology platform for patient-therapy alignment in a diverse set of human malignancies resistant to standard treatments

The paper validates an RNA-based platform for predicting drug sensitivity in treatment-resistant cancers using patient-derived xenograft models and multi-protein therapies.

Transcriptional deconvolution reveals consistent functional subtypes of pancreatic cancer epithelium and stroma

The paper develops an algorithm to deconvolve bulk tumor gene expression data and identifies consistent functional subtypes in pancreatic cancer epithelium and stroma.